Bioequivalence of Erythromycin Ethylsuccinate Granules Evaluated by HPLC-MS-MS

Chun Zhang
2008-01-01
Abstract:Objective: To develop a HPLC-MS-MS assay for determination of erythromycin ethylsuccinate and erythromycin in human plasma,and to estimate the bioequivalence of erythromycin ethylsuccinate and erythromycin in healthy volunteers.Methods: A random and crossover clinical trial was performed in 20 healthy volunteers,who took a single dose(0.5g) of either erythromycin ethylsuccinate granules or capsules.Plasma concentrations of erythromycin ethylsuccinate were determined by HPLC-MS-MS using roxithromycin as an internal standard.Results: Calibration curve of erythromycin ethylsuccinate was linear in the range of 2~2500μg·L-1,and the recovery was 73.1%~91.1%;while the calibration curve of erythromycin was linear in the range of 2~4000μg·L-1,and the recovery was 71.4%~91.7%.The main pharmacokinetic parameters of erythromycin ethylsuccinate were as follows: Cmax was(591±144) and(576±133) μg·L-1;Tmax was(0.80±0.39) and(0.81±0.40) h;t1/2 was(1.49±0.72) and(1.15±0.57) h;AUC0~t was(1085±304) and(1 074±301) μg·L-1·h.While the parameters of erythromycin were: Cmax was(1150±290) and(1158±318) μg·L-1;Tmax was(0.83±0.38) and(0.84±0.38) h;t1/2 was(2.68±0.51) and(2.58±0.75) h;AUC0~t was(2821±454) and(2887±545) μg·L-1·h.The relative bioavailability of erythromycin ethylsuccinate or erythromycin as estimated by AUC0~t was(106.1±12.8) % or(99.6±11.9)%,respectively.Conclusion: HPLC-MS-MS assay is proved to be sensitive,accurate and convenient,and can be applied to the pharmacokinetics of erythromycin ethylsuccinate in human.The two formulations of erythromycin ethylsuccinate are bioequivalent.
What problem does this paper attempt to address?